An in vitro study of several antibody therapies by Japanese researchers found diminished neutralisation of the Omicron variant and particularly of the BA.2 subvariant. Now a study at Washington University indicates that Evusheld and Sotrovimab both retain neutralising activity, while reducing viral load and lung inflammation in mice.
reuters.com/business/health...
This is the pre-print publication of the research findings, not peer reviewed. NB competing interest statement and concluding section Limitations of Study. biorxiv.org/content/10.1101...